Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA study, showing the subcutaneous version is as effective and safe as the intravenous form, with fewer infusion reactions. The subcutaneous formulation can be administered manually or via a portable on-body injector, potentially improving patient convenience. Sanofi is also seeking approval for this formulation in the US, marking a significant advance in multiple myeloma treatment options in Japan and globally.
Japan's Ministry of Health has approved Sanofi's Sarclisa subcutaneous (SC) formulation for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval is based on the IRAKLIA phase 3 study showing the SC form is...
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
COUR Pharma secured $50 million in a Series B funding round led by Lumira Ventures and Roche Venture Fund, with new investment from Sanofi. The funds will support clinical trials of CNP-103, a novel immune tolerance therapy targeting type 1 diabetes ...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
